Unicycive Therapeutics Stock Beta
| UNCY Stock | USD 0.74 0.05 7.25% |
Unicycive Therapeutics fundamentals help investors to digest information that contributes to Unicycive Therapeutics' financial success or failures. It also enables traders to predict the movement of Unicycive Stock. The fundamental analysis module provides a way to measure Unicycive Therapeutics' intrinsic value by examining its available economic and financial indicators, including the cash flow records, the balance sheet account changes, the income statement patterns, and various microeconomic indicators and financial ratios related to Unicycive Therapeutics stock.
Unicycive | Beta |
Unicycive Therapeutics Company Beta Analysis
Unicycive Therapeutics' Beta is one of the most important measures of equity market volatility. Beta can be thought of as asset elasticity or sensitivity to market. In other words, it is a number that shows the relationship of an equity instrument to the financial market in which this instrument is traded. For example, if Beta of equity is 2, it is expected to significantly outperform market when the market is going up and significantly underperform when the market is going down. Similarly, Beta of 1 indicates that an asset and market will generate similar returns over time.
Current Unicycive Therapeutics Beta | 2.29 |
Most of Unicycive Therapeutics' fundamental indicators, such as Beta, are part of a valuation analysis module that helps investors searching for stocks that are currently trading at higher or lower prices than their real value. If the real value is higher than the market price, Unicycive Therapeutics is considered to be undervalued, and we provide a buy recommendation. Otherwise, we render a sell signal.
Unicycive Beta Driver Correlations
Understanding the fundamental principles of building solid financial models for Unicycive Therapeutics is extremely important. It helps to project a fair market value of Unicycive Stock properly, considering its historical fundamentals such as Beta. Since Unicycive Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Unicycive Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Unicycive Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
In a nutshell, Beta is a measure of individual stock risk relative to the overall volatility of the stock market. and is calculated based on very sound finance theory - Capital Assets Pricing Model (CAPM).However, since Beta is calculated based on historical price movements it may not predict how a firm's stock is going to perform in the future.
| Competition |
In accordance with the recently published financial statements, Unicycive Therapeutics has a Beta of 2.286. This is 165.81% higher than that of the Biotechnology sector and 64.46% higher than that of the Health Care industry. The beta for all United States stocks is notably lower than that of the firm.
Unicycive Beta Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Unicycive Therapeutics' direct or indirect competition against its Beta to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Unicycive Therapeutics could also be used in its relative valuation, which is a method of valuing Unicycive Therapeutics by comparing valuation metrics of similar companies.Unicycive Therapeutics is currently under evaluation in beta category among its peers.
Unicycive Therapeutics Institutional Holders
Institutional Holdings refers to the ownership stake in Unicycive Therapeutics that is held by large financial organizations, pension funds or endowments. Institutions may purchase large blocks of Unicycive Therapeutics' outstanding shares and can exert considerable influence upon its management. Institutional holders may also work to push the share price higher once they own the stock. Extensive social media coverage, TV shows, articles in high-profile magazines, and presentations at investor conferences help move the stock higher, increasing Unicycive Therapeutics' value.| Shares | Geode Capital Management, Llc | 2024-09-30 | 402.4 K | Goldman Sachs Group Inc | 2024-09-30 | 93.4 K | Bleakley Financial Group Llc | 2024-09-30 | 80 K | Xtx Topco Ltd | 2024-09-30 | 70.8 K | Blackrock Inc | 2024-06-30 | 51.8 K | State Street Corp | 2024-09-30 | 43.9 K | Northern Trust Corp | 2024-09-30 | 24 K | Two Sigma Securities, Llc | 2024-09-30 | 23.3 K | Tower Research Capital Llc | 2024-09-30 | 22.8 K | Octagon Capital Advisors Lp | 2024-09-30 | 8.6 M | Logos Global Management Lp | 2024-09-30 | 5.1 M |
As the market goes up, the company is expected to outperform it. However, if the market returns are negative, Unicycive Therapeutics will likely underperform.
Unicycive Fundamentals
| Return On Equity | -1.22 | ||||
| Return On Asset | -0.53 | ||||
| Current Valuation | 39.97 M | ||||
| Shares Outstanding | 103.8 M | ||||
| Shares Owned By Insiders | 6.73 % | ||||
| Shares Owned By Institutions | 38.20 % | ||||
| Number Of Shares Shorted | 1.26 M | ||||
| Price To Book | 2.57 X | ||||
| Price To Sales | 62.82 X | ||||
| Revenue | 675 K | ||||
| EBITDA | (30.18 M) | ||||
| Net Income | (30.54 M) | ||||
| Cash And Equivalents | 10.57 M | ||||
| Cash Per Share | 0.70 X | ||||
| Total Debt | 811 K | ||||
| Debt To Equity | 0.02 % | ||||
| Current Ratio | 4.43 X | ||||
| Book Value Per Share | (0.11) X | ||||
| Cash Flow From Operations | (18.28 M) | ||||
| Short Ratio | 0.74 X | ||||
| Earnings Per Share | (0.46) X | ||||
| Target Price | 5.5 | ||||
| Number Of Employees | 14 | ||||
| Beta | 2.29 | ||||
| Market Capitalization | 71.51 M | ||||
| Total Asset | 14.19 M | ||||
| Retained Earnings | (64.54 M) | ||||
| Working Capital | (4.13 M) | ||||
| Net Asset | 14.19 M |
About Unicycive Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Unicycive Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Unicycive Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Unicycive Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Also Currently Popular
Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.Additional Tools for Unicycive Stock Analysis
When running Unicycive Therapeutics' price analysis, check to measure Unicycive Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Unicycive Therapeutics is operating at the current time. Most of Unicycive Therapeutics' value examination focuses on studying past and present price action to predict the probability of Unicycive Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Unicycive Therapeutics' price. Additionally, you may evaluate how the addition of Unicycive Therapeutics to your portfolios can decrease your overall portfolio volatility.